The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June ...
MedPage Today on MSN
FDA Expands Risankizumab Label in Psoriatic Disease
IL-23 inhibitor lands indications for kids 6 years and up ...
AbbVie ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s ABBV SKYRIZI (risankizumab-rzaa) for children ...
Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...
The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.
As a former claims handler and fraud investigator, Jason Metz has worked on a multitude of complex and multifaceted claims. The insurance industry can be seemingly opaque, and Jason enjoys breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results